Drug Information

Drug General Information
Drug ID
D0H4GT
Former ID
DIB007553
Drug Name
131I-radretumab
Synonyms
Radretumab; L-19; L-19-IgG1; L-19-SIP; Single chain Fv antibody fragment-based radioimmunotherapeutics, ETH Zurich/Bayer Schering/Philogen; Single chain Fv antibody fragment-based radioimmunotherapeutics, ETH Zurich/Schering/Philogen; L-19 based radioimmunotherapeutics (cancer), ETH Zurich/Bayer Schering/Philogen; L-19 based radioimmunotherapeutics (cancer), ETH Zurich/Schering/Philogen; ScFv-based radioimmunotherapeutics (cancer), ETH Zurich/Bayer Schering/Philogen; ScFv-based radioimmunotherapeutics (cancer), ETH Zurich/Schering/Philogen; 125I-L-19; 125I-L-19-IgG1; 125I-L-19-SIP
Drug Type
Antibody
Indication Non-small cell lung cancer [ICD10:C33-C34] Phase 1/2 [523256]
Company
ETH Zurich
Target and Pathway
Target(s) Integrin beta-1 Target Info [532756]
KEGG Pathway Rap1 signaling pathway
Phagosome
PI3K-Akt signaling pathway
Axon guidance
Focal adhesion
ECM-receptor interaction
Cell adhesion molecules (CAMs)
Platelet activation
Leukocyte transendothelial migration
Regulation of actin cytoskeleton
Bacterial invasion of epithelial cells
Pathogenic Escherichia coli infection
Shigellosis
Pertussis
Leishmaniasis
Toxoplasmosis
Pathways in cancer
Proteoglycans in cancer
Small cell lung cancer
Hypertrophic cardiomyopathy (HCM)
Arrhythmogenic right ventricular cardiomyopathy (ARVC)
Dilated cardiomyopathy
PANTHER Pathway Inflammation mediated by chemokine and cytokine signaling pathway
Integrin signalling pathway
CCKR signaling map ST
Pathway Interaction Database Signaling events mediated by PRL
RhoA signaling pathway
Beta1 integrin cell surface interactions
Integrin family cell surface interactions
Arf6 trafficking events
Reelin signaling pathway
Signaling events mediated by TCPTP
Angiopoietin receptor Tie2-mediated signaling
Alpha9 beta1 integrin signaling events
CXCR4-mediated signaling events
Plexin-D1 Signaling
Syndecan-4-mediated signaling events
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
a4b7 Integrin signaling
a6b1 and a6b4 Integrin signaling
Syndecan-2-mediated signaling events
Validated targets of C-MYC transcriptional repression
VEGFR3 signaling in lymphatic endothelium
Alpha4 beta1 integrin signaling events
Signaling events mediated by focal adhesion kinase
Reactome Elastic fibre formation
Fibronectin matrix formation
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Cell surface interactions at the vascular wall
Basigin interactions
Molecules associated with elastic fibres
Integrin cell surface interactions
Laminin interactions
Syndecan interactions
ECM proteoglycans
Other semaphorin interactions
Localization of the PINCH-ILK-PARVIN complex to focal adhesions
CHL1 interactions
RHO GTPases Activate Formins
Platelet Adhesion to exposed collagen
WikiPathways TGF beta Signaling Pathway
Signaling of Hepatocyte Growth Factor Receptor
Focal Adhesion
Hair Follicle Development: Organogenesis (Part 2 of 3)
Extracellular matrix organization
Elastic fibre formation
Nanoparticle-mediated activation of receptor signaling
JAK/STAT
Primary Focal Segmental Glomerulosclerosis FSGS
Pathogenic Escherichia coli infection
Arrhythmogenic Right Ventricular Cardiomyopathy
Neural Crest Differentiation
Semaphorin interactions
Platelet Adhesion to exposed collagen
Integrin-mediated Cell Adhesion
L1CAM interactions
Integrin cell surface interactions
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Cell surface interactions at the vascular wall
Cell junction organization
References
Ref 523256ClinicalTrials.gov (NCT01242943) Radioimmunotherapy With 131I-L19SIP in Patients With Cancer. U.S. National Institutes of Health.
Ref 532756Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP dosimetric PET study. Cancer Immunol Res. 2013 Aug;1(2):134-43.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.